Ixekizumab
Long-term ixekizumab similarly efficacious in challenging body areas in psoriasis
Patients with moderate to severe psoriasis in hard-to-treat areas of the body who received ixekizumab experienced long-term success over 5 years, according to a study.
Biologics Targeting Interleukin-17
Ixekizumab effective in psoriasis across racial groups, but patients report differences
Efficacy outcomes of ixekizumab through 12 weeks of treatment for psoriasis were consistent across multiple racial groups, although patient-reported outcomes were not, according to a study.
VIDEO: Psoriasis patients can switch medications, still receive effective treatment
In this Healio exclusive video, Raj Chovatiya, MD, PhD, discussed research into the interleukin-17 inhibitor ixekizumab from the Maui Derm 2024 meeting.
Ixekizumab reduces erosion, increases backfill scores in radiographic axial SpA
SAN DIEGO — Biologic-naïve patients with radiographic axial spondylarthritis who receive ixekizumab for 16 weeks demonstrate reduced erosion scores and increased backfill scores, according to data presented at ACR Convergence 2023.
VIDEO: Risankizumab improves psoriasis after poor response to secukinumab, ixekizumab
In this Healio video exclusive, Jashin J. Wu, MD, FAAD, discusses the benefits of switching patients with psoriasis to risankizumab after suboptimal response from secukinumab or ixekizumab treatment.
Ixekizumab demonstrates no new safety concerns over 3 years in axial spondyloarthritis
An analysis of long-term ixekizumab use over 3 years in patients with axial spondyloarthritis found no new safety signals, according to data published in The Journal of Rheumatology.
More than 95% of patients with axial SpA recapture LDA with ixekizumab after withdrawal
As many as 96% of patients with axial spondyloarthritis who withdrew from ixekizumab after a favorable response were able to recapture low disease activity, while 71% retained inactive disease, after resuming the drug, according to data.
Long-term quality of life improvements seen in children treated with ixekizumab
MILAN — Pediatric patients experienced improved psoriasis symptoms and quality of life with ixekizumab treatment, according to a poster presented at the European Academy of Dermatology and Venereology Congress.
Citrate-free Taltz now available
A citrate-free formulation of Taltz injection for patients is now available following its FDA approval earlier this year, Eli Lilly and Company announced in a press release.